Quick Answer
Mirum Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $521.31 million for the year ending 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +54.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Mirum Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.00 | Q3 2020: $0.00 | Q1 2021: $0.00 | Q2 2021: $11.00 million | Q3 2021: $5.00 million | Q1 2022: $12.89 million | Q2 2022: $17.48 million | Q3 2022: $18.78 million | Q1 2023: $31.60 million | Q2 2023: $37.50 million | Q3 2023: $47.73 million | Q1 2024: $69.22 million | Q2 2024: $77.88 million | Q3 2024: $90.38 million | Q1 2025: $111.59 million | Q2 2025: $127.79 million | Q3 2025: $133.01 million.
- Over the full 5 years of available data (2021 to 2025), Mirum Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 2,624.0%.
- Historical annual values: Fiscal year 2025: $521.31 million | Fiscal year 2024: $336.89 million | Fiscal year 2023: $186.37 million | Fiscal year 2022: $77.06 million | Fiscal year 2021: $19.14 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: